The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Wool.
Amazing. I think that says it all, no attempt to understand the company either when you bought the company or even now.
Just expected a one way ride with no risk.
No eshaitan, I haven't watched it, my interest is the SP. Good Luck.
Thanks a lot greatly appreciated
Dazed - Link is via Investor Meet: https://www.investormeetcompany.com (free registration).
Is it possible to have the link to watch the presentation, many thanks in advance
I must have been one of the last investors here to find the time to watch the presentation.
I thought it was very good. I think I asked the same questions as many others, so happy they were answered.
Cotton Head, I suggest you listen and digest the update.
thomascromwell. Unfortunately the bod have been saying good things for the past 12 months, today's shareprice is lower than May 2016, certain investors wonder why, I continually grouse......
Excellent Presentation and update. the future is looking very promising.
Excellent post AquaeSulis01,
Falls almost exactly with my viewpoint. I believe this company will do well, but not at previous expectations. SOH pointed to the "small print" in the goetz report saying that it wasnt a forecast with the normal caveats, and my more strongly worded question was watered down a bit, however in fairness didn't get ignored.
Although reassured by the investor update, agree with aqua on the discrete half year numbers. As I said on 23rd h2 to h2 growth was 29%.
I'm coming off the board until we have the final numbers were we have no understanding of the materiality of the numbers to show the real growth.
I think one of the issues with smaller companies is the level and frequency of reporting.
Anyway good luck to all holders, might be a traders share in the short term but still retain on longer term value.
Knowing how ultra cautions Stephen is, he wouldn't have issued that statement at half year if he had any inclination of the full extent of covid impact in H2. I don't think anyone was expecting such a strong resurgence beyond the first wave given how low levels were when the H1 report was issued. Clearly with hindsight, expectations were raised but it is what it is. Onwards.
Whilst revenue growth of 100% is certainly not shabby you do need to lift up the covers and dig a bit deeper. End Nov 2019 EOY report reported first half revenue of £149k and second half revenue of £659k (over 4 times greater) with a comment that whilst there would be some flattening out of the second half weighting in 2020 it would only be gradual. Fast forward to 2020 EOY Trading update, we have £745k 1st half revenue and £768k second half revenue; just 15% up which I would not describe as gradual smoothing.
All very well belatedly blaming covid, but the time to prepare investors for a severe impact was at the half year report, but instead we got this from the half year report where 400% growth and only minimal risk to sales for the remainder of the reporting year were forecast;
"Stephen O'Hara, CEO of OptiBiotix, commented: "This has been another period of exciting progress for OptiBiotix with a 400% increase in sales and a large reduction in costs compared to the same period last year. Our divisions are now making strong progress towards profitability with more agreements generating revenues, existing partners increasing sales, and more retail partners launching successful new products. Our products are now being commercialised with large retail and pharmaceutical partners boosting consumer awareness and confidence in our brands with OptiBiotix now being identified as a key player in the microbiome space within industry.
"The Company is now in a pivotal position of having a scalable business model growing sales from proven products with partners in multiple international territories in the human microbiome market, which is expected to grow at a CAGR of 22.60% between 2020 and 2025*. This presents us with a large and expanding market opportunity on which we are well placed to capitalise by increasing our range of applications, products and territories.
"Whilst uncertainty within the global economic environment will create challenges, we believe that our proven strategy of working with multiple partners, across different application areas and geographies within the healthcare sector, will limit the risk related to any individual deal, product, or geography, and we look forward to continued further progress over the year as a whole."
SOH summarised the point about growth pretty well, revenue up over 100%, gross margins up and administrative costs down about 25%. I know many were expecting much faster revenue growth by 100% isn’t exactly shabby. More encouraging were words on product extension at Holland and Barrett.
Exciting upside in Sweetbiotix over medium term.
Skin value will now post TW article be reflected in full in balance sheet.
SOH does deliver on his promises is my take but his approach is to diversify the risk across product line and levels.
I suspect 2021 will be profitable ex Skin fair value changes.
Cenkos as a larger broker may well start to generate new investor interest - the comparison withe other companies in space was encouraging.
Look up. ????
Hi aquae, on royalties I think the pie chart was the 1.5m they already had so you can't really tell.
Hoping this moves into mid 50s trading range until further updates.
Would be really nice to get back to woolys buy price to hopefully help his portfolio.
Agree skid and as a dual holder in both companies came as a relief
By the way would be nice to see elricos thoughts in his blog.
Aquae.
Thought he spoke well on skin. Just a reminder we are not really missing out on long term skin value as an indirect shareholder. When the time is right would be nice to hold these directly.
One other thing to add, I wouldn't hold my breath on o/s royalties changing the financials significantly, one presentation chart showed that 71% of all revenues are made up of ingredients and end products, with only 29% resulting from royalties so on total reported revenues of circa £1.5M wont make that much difference I would suggest.
Bogyo. I think you may have good timing. After results I thought this would drift from 50-65p so very much at the low end at the moment.
As you can probably my see from the board a number bought in over 70-80p so it's just what will change the trading range in the next 6 months (I am slightly loss making at 50p on a pretty hefty investment).
Key short term catalysts might be a major change from the 2020 with additional royalties counting, a major partner update or stbx just going North in a big way - or just a write up in an investor mag somewhere.
Yes was a very professional presentation.
Key take-outs for me were:
- Across the FY very good progress made and set of results however, second half of the reporting year was disappointing when compared to the first half being heavily impacted by Covid with partners unable to access end customer premises and hence not re-stocking. Things are now improving considerably.
- Very excited about sweetbiotix and believes this year will see commercial launches. Describes sweetbiotix as unique (acknowledged by a number of big end producers with Nestle mentioned). Will directly replace sugar in products allowing the labelling to move to green for both no sugar and high fibre than dual red at the moment on things such as chocolate bars, so really appealing for those producers. SOH considers sweetbiotix to be worth £50M - £60M on its own so with today's Market Cap only £44.41M for the whole company including its owned skinbiotiherapeutics asset (circa £15M) , shows how under valued Opti is.
No dividend on the back of selling down the skinbio shares until SOH considers the skinbio sp is representative of its true worth and he can sell without damaging skinbio strategically.
Dual NASDAQ listing still under consideration; seen as there being more opportunity than risk on balance
I am fairly new invested in OPTI, but I see a great potential with their products. I consider myself very lucky being able to buy at these prices. The SP tapped into this demand zone below 50p several times and seems very strong to reverse every time, so should head again to the demand zone and based on the pipeline of developments it will break up fairly soon.
Rebarm,
Agree, a good strategic overview at the start moving into operational detail. Didn't shirk any issues or questions and did explain, to some extent, h2. Obviously wanted to point to full year vs full year comparisons against lower / static growth h2 to h2 with no real indication of value of the royalties yet to be reported.
A good move from an investor relations perspective, and hopefully will have a more of a timetable of releases going forward into 2021.
Looking forward to a more final set of numbers for 2020 to really understand the financials, as well as further updates.
This has always been a long term holding for me, this presentation was therefore reassuring. Although a long term shareholder I do get uptight in waiting for updates and releases but understand the rules and requirements of a listed company - as well as the limited resources the company has to churn this stuff out.
Probably the best presentation I've heard from SOH. Good, clear information backed by an excellent slide set. Also he addressed many of the questions that are discussed frequently on this board. Despite the weak sp, I'm happy that there is a strong future for Opti.
I would though urge him to stick with platforms and deliveries like today's rather than the monotonous exchanges on other sites!